

**Supplementary Table 4.** Adjusted incidence of extrahepatic and intrahepatic malignancies in the propensity score-matched cohort

Diagnosis	Antiviral	Events, no. (%)	Within 3 years		After 3 years		Within 3 years		After 3 years		
			Incidence, per 1,000 person-year	95% CI	Incidence, per 1,000 person-year	95% CI	SHR (95% CI)	P-value	SHR (95% CI)	P-value	
Stomach	ETV	123 (0.5%)	0.92 (0.72–1.19)	[reference]	0.98 (0.77–1.26)	[reference]	1.03 (0.72–1.46)	[reference]	0.89	0.57 (0.38–0.86)	0.01
	TDF	101 (0.4%)	0.94 (0.74–1.20)		0.59 (0.42–0.82)						
Colorectal	ETV	85 (0.4%)	0.69 (0.51–0.93)	[reference]	0.63 (0.46–0.86)	[reference]	0.79 (0.51–1.22)	[reference]	0.28	1.04 (0.67–1.61)	0.87
	TDF	77 (0.3%)	0.54 (0.39–0.74)		0.65 (0.48–0.89)						
Lung	ETV	68 (0.3%)	0.39 (0.26–0.58)	[reference]	0.66 (0.49–0.89)	[reference]	0.86 (0.49–1.51)	[reference]	0.59	0.70 (0.43–1.13)	0.14
	TDF	52 (0.2%)	0.33 (0.22–0.50)		0.47 (0.33–0.66)						
Thyroid	ETV	118 (0.5%)	0.94 (0.73–1.21)	[reference]	0.89 (0.69–1.15)	[reference]	0.95 (0.67–1.36)	[reference]	0.80	0.75 (0.51–1.12)	0.16
	TDF	103 (0.4%)	0.89 (0.69–1.14)		0.69 (0.51–0.93)						
Breast (women only)	ETV	78 (0.3%)	0.36 (0.24–0.54)	[reference]	0.85 (0.65–1.10)	[reference]	1.74 (1.05–2.89)	[reference]	0.03	0.53 (0.33–0.85)	0.01
	TDF	71 (0.3%)	0.62 (0.46–0.84)		0.46 (0.32–0.66)						
Prostate (men only)	ETV	35 (0.1%)	0.19 (0.11–0.33)	[reference]	0.35 (0.24–0.53)	[reference]	0.92 (0.41–2.05)	[reference]	0.84	1.03 (0.57–1.86)	0.93
	TDF	33 (0.1%)	0.17 (0.10–0.31)		0.34 (0.22–0.53)						
Pancreas	ETV	24 (0.1%)	0.20 (0.12–0.35)	[reference]	0.17 (0.09–0.31)	[reference]	0.72 (0.31–1.65)	[reference]	0.44	0.75 (0.31–1.80)	0.52
	TDF	19 (0.1%)	0.15 (0.08–0.27)		0.15 (0.08–0.28)						
Gallbladder and biliary tract	ETV	14 (0.1%)	0.06 (0.02–0.17)	[reference]	0.15 (0.08–0.29)	[reference]	3.04 (0.99–9.34)	[reference]	0.05	0.77 (0.31–1.92)	0.58
	TDF	21 (0.1%)	0.19 (0.11–0.33)		0.13 (0.07–0.26)						
Kidney	ETV	30 (0.1%)	0.22 (0.13–0.37)	[reference]	0.25 (0.15–0.40)	[reference]	1.34 (0.68–2.67)	[reference]	0.40	0.71 (0.32–1.54)	0.38
	TDF	31 (0.1%)	0.29 (0.19–0.45)		0.18 (0.10–0.32)						
Non-Hodgkin lymphoma	ETV	42 (0.2%)	0.28 (0.18–0.45)	[reference]	0.37 (0.25–0.55)	[reference]	0.67 (0.33–1.37)	[reference]	0.28	0.34 (0.15–0.78)	0.01
	TDF	21 (0.1%)	0.19 (0.11–0.33)		0.13 (0.07–0.26)						
Liver (C22)	ETV	2,343 (9.7%)	20.19 (19.12–21.33)	[reference]	16.20 (15.25–17.21)	[reference]	0.88 (0.81–0.95)	[reference]	<0.01	0.68 (0.62–0.75)	<0.01
	TDF	1,911 (7.9%)	17.58 (16.62–18.60)		11.45 (10.63–12.33)						
Hepatocellular carcinoma (C22.0)	ETV	2,225 (9.2%)	19.27 (18.22–20.38)	[reference]	15.30 (14.37–16.28)	[reference]	0.87 (0.81–0.95)	[reference]	<0.01	0.68 (0.62–0.76)	<0.01
	TDF	1,812 (7.5%)	16.71 (15.77–17.70)		10.81 (10.02–11.66)						
Intrahepatic cholangiocarcinoma (C22.1)	ETV	31 (0.1%)	0.19 (0.11–0.33)	[reference]	0.29 (0.19–0.46)	[reference]	1.40 (0.68–2.90)	[reference]	0.37	0.89 (0.46–1.72)	0.73
	TDF	34 (0.1%)	0.26 (0.16–0.41)		0.26 (0.16–0.43)						

CI, confidence interval; ETV, entecavir; IQR, interquartile range; SHR, subdistribution hazard ratio; TDF, tenofovir disoproxil fumarate.